awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41807279-18EC9AF3-A9D7-46CA-BC23-99450BD7D57F
Q41807279-18EC9AF3-A9D7-46CA-BC23-99450BD7D57F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41807279-18EC9AF3-A9D7-46CA-BC23-99450BD7D57F
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
P2860
Q41807279-18EC9AF3-A9D7-46CA-BC23-99450BD7D57F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41807279-18EC9AF3-A9D7-46CA-BC23-99450BD7D57F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dd891f69f57094da8d290210d49f12fc67164e3e
P2860
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.